Short Communication: HIV-1 Variants That Use Mouse CCR5 Reveal Critical Interactions of gp120's V3 Crown with CCR5 Extracellular Loop 1

被引:1
|
作者
Platt, Emily J. [1 ]
Durnin, James P. [1 ]
Kabat, David [1 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97239 USA
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR CCR5; ENVELOPE GLYCOPROTEIN; ADAPTIVE MUTATIONS; AMINO-TERMINUS; N-TERMINUS; CORECEPTOR; ENTRY; BINDING; FUSION;
D O I
10.1089/aid.2015.0131
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The CCR5 coreceptor amino terminus and extracellular (ECL) loops 1 and 2 have been implicated in HIV-1 infections, with species differences in these regions inhibiting zoonoses. Interactions of gp120 with CD4 and CCR5 reduce constraints on metastable envelope subunit gp41, enabling gp41 conformational changes needed for infection. We previously selected HIV-1(JRCSF) variants that efficiently use CCR5(Delta 18) with a deleted amino terminus or CCR5(HHMH) with ECL2 from an NIH/Swiss mouse. Unexpectedly, the adaptive gp120 mutations were nearly identical, suggesting that they function by weakening gp120's grip on gp41 and/or by increasing interactions with ECL1. To analyze this and further wean HIV-1 from human CCR5, we selected variants using CCR5(HMMH) with murine ECL1 and 2 sequences. HIV-1(JRCSF) mutations adaptive for CCR5(Delta 18) and CCR5(HHMH) were generally maladaptive for CCR5(HMMH), whereas the converse was true for CCR5(HMMH) adaptations. The HIV-1(JRCSF) variant adapted to CCR5(HMMH) also weakly used intact NIH/Swiss mouse CCR5. Our results strongly suggest that HIV-1(JRCSF) makes functionally critical contacts with human ECL1 and that adaptation to murine ECL1 requires multiple mutations in the crown of gp120's V3 loop.
引用
收藏
页码:992 / 998
页数:7
相关论文
共 50 条
  • [11] NMR conformational studies of the interaction between the V3 loop of HIV-1 coat glycoprotein gp120 and chemokine receptor CCR5, at peptide level
    Galanakis, PA
    Kandias, N
    Spyroulias, GA
    Sioumpara, M
    Morikis, D
    Rizos, A
    Krambovitis, E
    FEBS JOURNAL, 2005, 272 : 548 - 548
  • [12] NMR structural analysis of the HIV-1 GP120 V3 - CCR5 co-receptor N-terminal interaction
    Galanakis, P. A.
    Kandias, N.
    Spyroulias, G. A.
    Sioumpara, M.
    Morikis, D.
    Rizos, A.
    Krambovitis, E.
    JOURNAL OF PEPTIDE SCIENCE, 2006, 12 : 196 - 196
  • [13] Analysis of the HIV-1 gp120 V3 loop at screening for treatment-experienced patients in the MOTIVATE studies who failed with CCR5 tropic virus
    Lewis, M.
    Simpson, P.
    Jubb, B.
    Craig, C.
    Valdez, H.
    Westby, M.
    ANTIVIRAL THERAPY, 2010, 15 : A76 - A76
  • [14] A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5
    Zhao, Q
    He, YX
    Alespeiti, G
    Debnath, AK
    VIROLOGY, 2004, 326 (02) : 299 - 309
  • [15] Two HIV-1 Variants Resistant to Small Molecule CCR5 Inhibitors Differ in How They Use CCR5 for Entry
    Berro, Reem
    Sanders, Rogier W.
    Lu, Min
    Klasse, Per J.
    Moore, John P.
    PLOS PATHOGENS, 2009, 5 (08)
  • [16] Electrostatic modeling of peptides derived from the V3-loop of HIV-1 gp120: Implications of the interaction with chemokine receptor CCR5
    Morikis, Dimitrios
    Rizos, Apostolos K.
    Spandidos, Demetrios A.
    Krambovitis, Elias
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2007, 19 (03) : 343 - 351
  • [17] CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation site
    Clevestig, P
    Pramanik, L
    Leitner, T
    Ehrnst, A
    JOURNAL OF GENERAL VIROLOGY, 2006, 87 : 607 - 612
  • [18] Gp120 V3-dependent impairment of R5 HIV-1 infectivity due to virion-incorporated CCR5
    Monde, Kazuaki
    Maeda, Yosuke
    Tanaka, Yuetsu
    Harada, Shinji
    Yusa, Keisuke
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (51) : 36923 - 36932
  • [19] Staphylococcus aureus Leukocidin LukED and HIV-1 gp120 Target Different Sequence Determinants on CCR5
    Tam, Kayan
    Schultz, Megan
    Reyes-Robles, Tamara
    Vanwalscappel, Benedicte
    Horton, Joshua
    Alonzo, Francis, III
    Wu, Beili
    Landau, Nathaniel R.
    Torres, Victor J.
    MBIO, 2016, 7 (06):
  • [20] Differential use of CCR5 by HIV-1 clinical isolates resistant to small molecule CCR5 inhibitors
    Henrich, T. J.
    Lewine, N.
    Lee, S-H
    Rao, S.
    Berro, R.
    Greaves, W.
    Gulick, R.
    Tsibris, A.
    Moore, J.
    Kuritzkes, D.
    ANTIVIRAL THERAPY, 2011, 16 : A59 - A59